Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Phase 4 Recruiting 220 enrolled China National Center for Cardiovascular Diseases Chinese Academy of Medical Sciences · collab Chinese Academy of Medical Sciences, Fuwai Hospital · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Timeline

Start: 2025-06-05
Primary completion: 2026-12
Completion: 2027-06

Publications

Tiemuerniyazi X, Chen L, He L, Yang Z, Huang S, Nan Y, Song Y, Yuan X, Hu Z, Zhao D, Zhao W, Feng W. The Role of Angiotensin Receptor/Neprilysin Inhibitor in Moderate Ischemic Mitral Regurgitation After Isolated Coronary Artery Bypass Grafting (ARNI-MIMIC): Study Protocol for a Randomized Controlled Trial. Am J Cardiol. 2025 Dec 1;256:102-106. doi: 10.1016/j.amjcard.2025.08.029. Epub 2025 Aug 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	sacubitril/valsartan	Unknown	—	—

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Summary

Timeline

Publications

Drugs

Indications